Results 231 to 240 of about 488,841 (318)

Melanoma Diagnosis in the Mihm Era—And Beyond

open access: yesJournal of Cutaneous Pathology, Volume 53, Issue 1, Page 16-22, January 2026.
ABSTRACT During the illustrious career of Martin C. Mihm Jr., MD, the diagnosis of melanoma underwent significant changes, to which he made many contributions. In early descriptions, melanomas were fungating tumor masses that were obviously malignant, and highly lethal. In seminal work by Dr. Mihm and his mentor, Wallace H.
David E. Elder
wiley   +1 more source

Atypical Ductal Hyperplasia Diagnosis by Directional Vacuum-Assisted Stereotactic Biopsy of Breast Microcalcifications: Considerations for Surgical Excision [PDF]

open access: bronze, 2003
Nour Sneige   +6 more
openalex   +1 more source

Atypical Ductal Hyperplasia Bordering on Ductal Carcinoma In Situ

open access: yesInternational Journal of Surgical Pathology, 2017
G. Tozbikian   +8 more
semanticscholar   +1 more source

Treatment‐related changes in the prostate: past, present and future therapies

open access: yesHistopathology, Volume 88, Issue 1, Page 40-52, January 2026.
Radiation therapy alters tumour morphology and immunoprofile in prostate cancer. Residual carcinoma shows distorted glandular architecture on H&E and loss of basal markers with preserved AMACR expression by immunohistochemistry, aiding in the recognition of treatment effect in prostate biopsies.
Katrina Collins, Liang Cheng
wiley   +1 more source

Induction of Atypical Ductal Hyperplasia in Mouse Mammary Gland Organ Culture [PDF]

open access: bronze, 2001
Rajendra G. Mehta   +8 more
openalex   +1 more source

Value of breast MRI for patients with a biopsy showing atypical ductal hyperplasia (ADH)

open access: yesJournal of Magnetic Resonance Imaging, 2017
K. Tsuchiya   +6 more
semanticscholar   +1 more source

Molecular pathology of testicular germ cell tumours: an update for practicing pathologists

open access: yesHistopathology, Volume 88, Issue 1, Page 214-229, January 2026.
Molecular testing for isochromosome 12p is usually only necessary in difficult cases that encompass metastases or recurrent diseases including somatic‐type malignancies. So far, no breaking progress has been made in the field of targeted therapy as TGCTs only rarely show targetable molecular alterations.
Alexander Fichtner   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy